Metastatic Gastric Adenocarcinoma

Oncology·MeSH: Neoplasm Metastasis

9 drugs in development·2 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
intravenous tislelizumab	BeOne Medicines Ltd. (ONC)
Intravenous Tislelizumab	BeOne Medicines Ltd. (ONC)
leucovorin	BeOne Medicines Ltd. (ONC)
Leucovorin	BeOne Medicines Ltd. (ONC)
subcutaneous tislelizumab	BeOne Medicines Ltd. (ONC)
Subcutaneous Tislelizumab	BeOne Medicines Ltd. (ONC)

Phase 2(2)

Drug	Company
Budigalimab	AbbVie Inc. (ABBV)
Leucovorin	AbbVie Inc. (ABBV)

Phase 2/Phase 3(1)

Drug	Company
Telisotuzumab Adizutecan	AbbVie Inc. (ABBV)

Compare drugs

intravenous tislelizumab vs leucovorin intravenous tislelizumab vs subcutaneous tislelizumab intravenous tislelizumab vs Budigalimab

Frequently asked questions

How many drugs are in development for Metastatic Gastric Adenocarcinoma?

BioSniper tracks 9 drugs in development for Metastatic Gastric Adenocarcinoma across 2 companies.

How many clinical trials target Metastatic Gastric Adenocarcinoma?

There are 6 clinical trials targeting Metastatic Gastric Adenocarcinoma tracked by BioSniper.

Deep-dive into Metastatic Gastric Adenocarcinoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Metastatic Gastric Adenocarcinoma — Drugs in Development & Clinical Trials | BioSniper